Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03593603 · ClinicalTrials.gov registry record
Trending of Respiratory Rate Using the Nellcor™ Bedside Respiratory Patient Monitoring System
A clinical trial of Patients Prescribed Non-invasive Respiratory Monitoring, sponsored by Medtronic - MITG.
- Completed
- Registry status
- 37
- Enrollment target
- 2
- Study locations
NCT03593603: Completed study of Patients Prescribed Non-invasive Respiratory Monitoring, sponsored by Medtronic - MITG.
NCT03593603 is a study of Patients Prescribed Non-invasive Respiratory Monitoring that has completed, run by Medtronic - MITG. The registered enrollment target is 37 participants. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03593603, a study of Patients Prescribed Non-invasive Respiratory Monitoring, has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open-label, non-randomized, prospective, descriptive study of the Nellcor™ Bedside Respiratory Patient Monitoring System using the Nellcor™ Respiration Rate parameter and Nellcor™ Adult Respiratory Sensor The study is intended to gain further information in the clinical space on the function of the Nellcor™ Respiration Rate parameter. The primary objective is to describe spot check (e.g. manual observation) of respiration rate versus cumulative automated counting (trend) of respiratory rate as measured using the Nellcor™ Bedside Respiratory Patient Monitoring System with the Nellcor™ Respiration Rate parameter.
Primary Outcome
Bias and a range of agreement of the differences between RR measured by spot checks and RR measured using the Nellcor™ Bedside Respiratory Patient Monitoring System
Conditions Studied
Interventions
- DEVICE Nellcor™ Bedside Respiratory Monitoring System
Study Locations (2)
Oklahoma
- St. John Health System - Tulsa
Washington
- MultiCare Institute for Research & Innovation - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2018-07-11 |
| Est. Completion | 2019-05-03 |
What the finished NCT03593603 record still lists
NCT03593603 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target.
The record links to 1 condition, with Patients Prescribed Non-invasive Respiratory Monitoring appearing as the primary indexed condition, and to 1 intervention - of which Nellcor™ Bedside Respiratory Monitoring System is the first listed.
NCT03593603 reports a single indexed study location in Oklahoma, Washington.
Frequently Asked Questions
What is clinical trial NCT03593603 about?
NCT03593603 is a clinical study titled "Trending of Respiratory Rate Using the Nellcor™ Bedside Respiratory Patient Monitoring System". This is an open-label, non-randomized, prospective, descriptive study of the Nellcor™ Bedside Respiratory Patient Monitoring System using the Nellcor™ Respiration Rate parameter and Nellcor™ Adult Respiratory Sensor The study is intended to gain further information in the clinical space on the funct...
What is the current status of trial NCT03593603?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2018-07-11. Estimated completion is 2019-05-03.
What conditions does trial NCT03593603 study?
This clinical trial studies the following conditions: Patients Prescribed Non-invasive Respiratory Monitoring.
What interventions are being tested in trial NCT03593603?
The interventions under investigation include: Nellcor™ Bedside Respiratory Monitoring System (DEVICE).
Who is sponsoring clinical trial NCT03593603?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03593603 being conducted?
This trial has 2 study locations across Oklahoma, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI